文献速递肿瘤 PET/CT

人工智能在肿瘤分子PET显像中的应用:超越[18F]F-FDG示踪剂的叙述性综述——第一部分:PSMA、胆碱和DOTA类示踪剂

Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [18F]F-FDG Tracers - Part I. PSMA, Choline, and DOTA Radiotracers.
PubMed 文献 · Semin Nucl Med · 2023-09-24

本叙述性综述聚焦超越[18F]F-FDG的非FDG示踪剂(PSMA、胆碱和DOTA类)在肿瘤分子PET显像中的人工智能应用。PSMA模型在肿瘤病灶定位和勾画方面高度准确,并可预测治疗反应和患者生存;胆碱显像结果可接受但证据有限;DOTA配体可诊断疑难部位肿瘤并预测组织病理学分级。当前研究有限但结果有前景。

要点

  • PSMA模型在确定肿瘤病灶位置和勾画方面高度准确,尤其在前列腺腺体内。
  • PSMA PET人工智能可预测治疗反应和患者生存,对患者管理至关重要。
  • 胆碱显像结果可接受但证据显著少于PSMA;DOTA配体可预测组织病理学分级。

核心结论

  • 当前有限的研究显示了有前景的结果,指向人工智能在超越[18F]F-FDG的分子显像中的光明未来。

研究设计与样本

  • 叙述性综述,聚焦超越[18F]F-FDG的示踪剂(PSMA、胆碱和DOTA类)在肿瘤分子PET显像中的人工智能应用。

主要发现

  • PSMA模型在确定肿瘤病灶位置和勾画方面高度准确,尤其在前列腺腺体内,并可自动评估全身图像以检测前列腺外病灶。
  • PSMA PET人工智能可预测治疗反应和患者生存。
  • 胆碱显像结果可接受,可能对临床有益,但当前证据显著少于PSMA。
  • 不同亚型DOTA配体可诊断疑难部位肿瘤病灶并预测组织病理学分级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 当前研究有限。
  • 胆碱显像的当前证据显著少于PSMA。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Artificial intelligence (AI) has evolved significantly in the past few decades. This thriving trend has also been seen in medicine in recent years, particularly in the field of imaging. Machine learning (ML), deep learning (DL), and their methods (eg, SVM, CNN), as well as radiomics, are the terminologies that have been introduced to this field and, to some extent, become familiar to the expert clinicians. PET is one of the modalities that has been enhanced via these state-of-the-art algorithms. This robust imaging technique further merged with anatomical modalities, such as computed tomography (CT) and magnetic resonance imaging (MRI), to provide reliable hybrid modalities, PET/CT and PET/MRI. Applying AI-based algorithms on the different components (PET, CT, and MRI) has resulted in promising results, maximizing the value of PET imaging. However, [18F]F-FDG, the most commonly utilized tracer in molecular imaging, has been mainly in the spotlight. Thus, we aimed to look into the less discussed tracers in this review, moving beyond [18F]F-FDG. The novel non-[18F]F-FDG agents also showed to be valuable in various clinical tasks, including lesion detection and tumor characterization, accurate delineation, and prognostic impact. Regarding prostate patients, PSMA-based models were highly accurate in determining tumoral lesions' location and delineating them, particularly within the prostate gland. However, they also could assess whole-body images to detect extra-prostatic lesions in a patient automatically. Considering the prognostic value of prostate-specific membrane antigen (PSMA) PET using AI, it could predict response to treatment and patient survival, which are crucial in patient management. Choline imaging, another non-[18F]F-FDG tracer, similarly showed acceptable results that may be of benefit in the clinic, though the current evidence is significantly more limited than PSMA. Lastly, different subtypes of DOTA ligands were found to be valuable. They could diagnose tumoral lesions in challenging sites and even predict histopathology grade, being a highly advantageous noninvasive tool. In conclusion, the current limited investigations have shown promising results, leading us to a bright future for AI in molecular imaging beyond [18F]F-FDG.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mirshahvalad SA, Eisazadeh R, Shahbazi-Akbari M, et al. Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [18F]F-FDG Tracers - Part I. PSMA, Choline, and DOTA Radiotracers. Semin Nucl Med. 2023. PMID: 37752032. doi:10.1053/j.semnuclmed.2023.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。